|Bid||57.62 x 1300|
|Ask||59.00 x 1200|
|Day's range||56.58 - 58.07|
|52-week range||42.48 - 68.34|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||28.79|
|Forward dividend & yield||1.80 (3.11%)|
|1y target est||70.45|
Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.
FDA Approves Reblozyl®, the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Bristol Myers Squibb & bluebird bio Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
BMS Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA for the Treatment....
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
Zacks.com featured highlights include: Bristol-Myers Squibb, AmerisourceBergen, Leidos, Xcel Energy and Caseys General Stores
NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.